bpc-157 intranasal administration study Frontiers bpc 157 injection vs nasal

SLU-PP-332 (50 mg/kg, i.p., twice per day for 28 days or 12 days) induces fatty acid metabolism, reduces fat mass and improves glucose metabolism in diet-induced obesity mouse models [3]

The promise is real, but clinical readiness is not: Preclinical and early human data are compelling, but without large-scale trials, validated delivery methods, and long-term safety data, Epitalon remains an experimental peptide, one to watch closely, but not yet ready for mainstream clinical adoption

A., Bozymski, E

The influx of calcium then activates proteases that cleave proglucagon peptides, ultimately boosting GLP-1 production

Safety vs